Keating, C., Yonker, L. M., Vermeulen, F., Prais, D., Linnemann, R. W., Trimble, A., Kotsimbos, T., Mermis, J., Braun, A. T., O’Carroll, M., Sutharsan, S., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Floreth, T., Michelson, P., Sosnay, P. R., … Horsley, A. (2025). Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00411-9

Burdis, N., Milinic, T., Bartlett, L. E., Goss, L., Tallarico, E., Boyle, A., Thaxton, A., Turner, G. A., Benvenuto, L. J., Faro, A., Goss, C. H., Kapnadak, S. G., & Ramos, K. J. (2024). A survey of cystic fibrosis physicians’ views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology, 59(12), 3641–3649. Portico. https://doi.org/10.1002/ppul.27273

Li, G., Wang, L., Ye, F., Li, S., & Yu, H. (2024). Molecular determinants of olfactory receptor activation: Comparative analysis of Olfr205 and Olfr740 family member responses to indole. Archives of Biochemistry and Biophysics, 758, 110061. https://doi.org/10.1016/j.abb.2024.110061

Rose, N. R., Chalamalla, A. R., Garcia, B. A., Krick, S., Bergeron, J., Sadeghi, H., Schellhase, D. E., Ryan, K. J., Dowell, A. E., Acosta, E. P., & Guimbellot, J. S. (2024). Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulmonary Pharmacology & Therapeutics, 86, 102301. https://doi.org/10.1016/j.pupt.2024.102301

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Berry-Kravis, E., Abbeduto, L., Hagerman, R., Coffey, C. S., Cudkowicz, M., Erickson, C. A., McDuffie, A., Hessl, D., Ethridge, L., Tassone, F., Kaufmann, W. E., Friedmann, K., Bullard, L., Hoffmann, A., Veenstra-VanderWeele, J., Staley, K., Klements, D., Moshinsky, M., Harkey, B., … Pearson, B. (2023). Effects of AFQ056 on language learning in fragile X syndrome. Journal of Clinical Investigation, 134(5). https://doi.org/10.1172/jci171723

Heneghan, L. J., Tsang, A., Dimino, C., Khandji, A. G., Panigrahi, S. K., & Page-Wilson, G. (2023). Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability. The Journal of Clinical Endocrinology & Metabolism, 109(2), e667–e674. https://doi.org/10.1210/clinem/dgad545

Miller, J. E., Taylor‐Cousar, J. L., Overdevest, J. B., Khatiwada, A., Mace, J. C., Alt, J. A., Bodner, T. E., Chowdhury, N. I., DiMango, E. A., Eshaghian, P. H., Getz, A. E., Gudis, D. A., Han, E. J., Hwang, P. H., Keating, C. L., Khanwalkar, A., Kimple, A. J., Lee, J. T., Li, D., … Beswick, D. M. (2023). Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. International Forum of Allergy & Rhinology, 14(6), 1079–1087. Portico. https://doi.org/10.1002/alr.23312

Kim, J. S., Murray, S., Yow, E., Anstrom, K. J., Kim, H. J., Flaherty, K. R., Martinez, F. J., & Noth, I. (2024). Comparison of Pirfenidone and Nintedanib. CHEST, 165(5), 1163–1173. https://doi.org/10.1016/j.chest.2023.11.035